Figure 3.
Molecular COO and copy number alterations in HLA class I/II alleles and antigen presentation/processing genes, separated into the PCNSL subtypes. (A) Stacked histograms show the relationship between the molecular COO classification (using the Lymph2CX assay) across 3 subtypes. Because EBV− HIV+ PCNSL represented only 2 COO cases, aggregate data are not shown. UC, unclassified. (B) Each column represents an individual case across the 4 PCNSL subtypes. Copy number altered genes constitute individual rows, with gains and losses shown in gold and blue, respectively. On the far right, percentages indicate the proportion of PCNSL tumors with copy number alterations of the specified gene; red* brain lymphoma TK cell-line, red** patients without PTLD/iatrogenic immunosuppression.

Molecular COO and copy number alterations in HLA class I/II alleles and antigen presentation/processing genes, separated into the PCNSL subtypes. (A) Stacked histograms show the relationship between the molecular COO classification (using the Lymph2CX assay) across 3 subtypes. Because EBV− HIV+ PCNSL represented only 2 COO cases, aggregate data are not shown. UC, unclassified. (B) Each column represents an individual case across the 4 PCNSL subtypes. Copy number altered genes constitute individual rows, with gains and losses shown in gold and blue, respectively. On the far right, percentages indicate the proportion of PCNSL tumors with copy number alterations of the specified gene; red* brain lymphoma TK cell-line, red** patients without PTLD/iatrogenic immunosuppression.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal